Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.
I agree it would be extremely disapointing if the next RNS was regurgitating the same as previous news releases
They have had a few years at it now since coming to market so as Neil says we should be close to something! Either a sries of RNS updates or some significant news.
I was about to post the same message Neil, it was all baked into the legal agreements of the PUT option and now it is down to us to draw funds down from our Conduit shares as and when required based on when we need them instead of having a placing to raise funds. win/win
The option which has been exercised, when settled, will allow CIZ to sell any number of shares when they want. If the CDT price is a little low or a little high it still gives a large chunk of change to progress through to commercialisation without the need for fund raising via a placing so great news for us shareholders. This was always a nice bonus for the business and not about our product.
A very positive update
Thanks Neil and yes I agree the Murph/Conduit merger and put option gives us a bonus with even more short term security against any requirement to fund raise but there will be more revenue opportunities to come.
With the feasibility being successful as stated in the RNS this could mean the exciting times ahead are a step closer.
I agree I think the only reason they previously raised is the Murph/Conduit merger got delayed a little. With this all falling into place next month then Ciz will have a tap of funding that they can turn on and off to suit their next development steps which will take us to commercialisation.
I think we are sort of saying the same thing essentially we have to PUT and then we can get the cash via sale of the shares if we donāt put they could CALL (or not) either way when done thereās a cash pot available from the subsequent share sale and personally Iād rather have that in the bank for the costs associated with finalising testing and commercialisation
Basically the way the transaction works is that there is usually a PUT and CALL agreement. We as holders of shares in Conduit have the right to PUT our shares up for purchase. Conduit will have an option to CALL the shares and purchase them back if we donāt PUT them up for purchase. Usually both are to a defined timeline.
In our case if we exercise our option and have have PUT our shares up to be purchased back by Conduit. As soon as the deal is done we will receive the cash which is the Ā£3.25million.
If we donāt PUT them up and keep hold in hope that they may be worth more in the future Conduit may CALL them in and purchase them anyway for whatever they are worth at the time.
If I were on the board of CIZ Iād exercise the PUT and pocket the Ā£3.25M and we are sorted for funds which will see us well into commercialisation and revenue generation without a requirement to fund raise.
No Brainer really
Rubber stamps our cash position and de risks future capital raises for Ciz. With nearly half the current Ciz MCap of Ā£3.25Million available to us as additional funds, this is hugely positive for the final steps to conclude our commercial trials and take our product to Market.
Could not be any clearer in that short interview.
Proof of Concept and research done
Trials on Proof of Concept and research done
MAB's done
Commercial Test Platform for the Lab Developed Tests ACHIEVED
Scaling up under way to allow Commercial Testing of the LDT platform and results to be done
Scaling up will also then allow our partners to penetrate the market and gain revenues.
Sounds like we are not very far away now provided the results of the commercial LDT give a similar accuracy as the research testing results
And well funded
I think that is a very positive position for us and if the commercial test is anywhere near the accuracy of the research tests that would be massive, especially given the inaccuracies and false positives of competition products.
Sounds like they have cracked it, the key was development of the MABās which unlocks the next stage of development and they are saying they have done this.
They say this key milestone has been met and as such they are now engaged in the design stage for clinical trials.
And they also mention that this is being applied to a new high throughput immunoassay platform
All very positive me thinks
I agree CT Scans are just one aspect to early detection and sadly Lung Cancer and other forms of cancer are not going to be cured overnight with this early detection. There is a huge market for CIZ amongst other players in the field. Also the sentence below within the article is interesting. What other announcements are they planning to make we have had Grail, now CT scans there may also be one for us?
The rollout of lung screening is expected to form part of a series of announcements this year to improve early diagnosis of cancer.
This does not sound like it detects early to me. Far lower percentage success rate and good at detecting advanced cancers. Ciz detects Lung cancer at Stage 1 with a higher percentage success rate.
The test correctly revealed two-thirds of cancers among those in the study. In 85% of those positive cases, it was also able to pinpoint the original site of cancer. It was more accurate in older patients, and those with more advanced cancers, according to the trial results.
Not necessarily greedy directors, more strategic I would think. My previous business was bought out by a multi billion european business. The deal was made to fully acquire the business after a 3 year period with Share Options granted to all existing Directors (of which I was a minor shareholder) on a yearly gateway following the deal being signed.
We have all been chatting about the potential for the business to be bought out by the big boys. Could it be that an acquisition deal is being explored which would result in the options being exercised over the next couple of years as they are bought out by a larger business?